Objective: The goal of this study was to analyze the economic benefits of introducing the 7-valent pneumococcal conjugate vaccine (PCV7) into the City Immunity Program in Shanghai. Methods: A decision-analytic model designed for pneumococcal disease and outcomes of pneumococcal infection was populated with local, agespecific incidence and cost data to estimate the expected economic benefits from vaccinating a birth cohort of 172,183 infants in Shanghai over a 1-year period using a cross-sectional approach. The analysis was assumed to occur in a year at which time the direct and indirect effects of vaccination have reached a steady state. Costs were calculated from a payer perspective and included vaccination program costs and direct medical expenditures from pneumococcalrelated disease. Results: The model predicts that 112,629 cases of pneumococcal-related disease could be prevented during a given year following the introduction of the PCV7 vaccine into the City Immunity Program in Shanghai, leading to a reduction of ¥187,923,359 (US $29,067,790) in direct medical costs. Overall, the inclusion of the PCV7 vaccine is estimated to have a cost-per-life-year saved of ¥37,468 (US $5,796) and a cost-per-quality-adjusted-life-year gained of ¥41,603 (US $6,435) when both the direct and indirect effects of the vaccine resulting from herd protection are taken into account. Conclusions: Results suggest that including PCV7 into the City Immunity Program in Shanghai could be considered cost-effective under generally accepted willingness-to-pay thresholds when both the direct and indirect effects of the vaccine are considered in the analysis.
Introduction
Streptococcus pneumoniae, which can result in both invasive diseases, such as bacteremic pneumonia, septicemia, and meningitis, and noninvasive diseases, such as pneumonia, otitis media, and sinusitis infections, is a leading cause of respiratory disease globally. One of the key risk factors for pneumococcal disease is age, with children younger than 5 years and the elderly being at the highest risk of developing pneumococcal-related infection. Pneumococcal disease is estimated to be the leading cause of vaccine-preventable morbidity and mortality among children younger than 5 years both globally and in China [1, 2] . The World Health Organization has reported that approximately 1.6 million people die each year from pneumococcal-related diseases. Among this group, approximately 700,000 to 1 million are children younger than 5 years [3] . In addition to the mortality associated with pneumococcal-related diseases, there exists a significant effect on the overall quality of life among those inflicted with the disease, as well as a large economic burden for both patients and society.
The 7-valent pneumococcal conjugate vaccine (PCV7) was licensed for use in the United States in February 2000 and was subsequently recommended for routine vaccination of all infants in the United States starting at age 2 months [4] . Since its addition to the recommended vaccination schedule, the vaccine has had a dramatic effect on the incidence of pneumococcal-related disease due largely to the indirect effect from herd protection on unvaccinated children and adults [5, 6] . A report by the Centers for Disease Control and Prevention indicates that most of the reduction in invasive pneumococcal disease (IPD) cases following the introduction of PCV7 into the routine vaccination schedule among infants in the United States was due to the indirect effect on the unvaccinated population by reducing the nasopharyngeal carriage of Streptococcus pneumoniae among immunized children [7] .
The PCV7 vaccine contains seven serotypes: 4, 6B, 9 V, 14, 18C, 19 F, and 23 F. Although there are more than 90 known pneumococcal serotypes, a relatively small number account for most of the pneumococcal-related disease globally [8, 9] , and it is estimated that the serotypes contained in the PCV7 vaccine would account for approximately 76% of the serotypes associated with pneumococcal disease prevalent among children younger than 5 years in China [10] . As a result of both the impressive safety and effectiveness record of the PCV7 vaccine in the United States and elsewhere over the past decade, the World Health Organization has recommended the inclusion of PCV7 in childhood immunization programs worldwide [11] .
Although there have been a number of studies demonstrating the cost-effectiveness of introducing PCV7 into the national immunization programs of various countries in Asia [12] [13] [14] [15] [16] [17] , there has not yet been an analysis of the potential economic effect of adding PCV7 to the routine childhood vaccination schedule in China. In this study, for several reasons, we focus attention on PCV7 rather than alternative, higher valency versions of the pneumococcal vaccine. At the time of this writing, PCV7 is the only pneumococcal conjugate vaccine that is approved for use in China, and it is currently listed as a type 2 vaccine on the Expanded Program Immunization, making it nonmandatory and not reimbursed [18, 19] . Furthermore, higher valency pneumococcal vaccines, such as the 13-valent pneumococcal conjugate vaccine, are unlikely to be available in China before 2016. To estimate the effect of PCV7 in China, this study applies demographic, epidemiological, and medical cost data from local and regional sources to a mathematical model designed to estimate both the clinical and economic benefits of the PCV7 vaccine, and incorporates both the direct effect of the vaccine on children in Shanghai and the indirect effects of herd protection on the unvaccinated child and adult population. Given the lack of availability of higher valency versions of the pneumococcal conjugate vaccine in China, it would be difficult to effectively populate the model with local, Chinese-specific data necessary for a relevant evaluation of the effect of the vaccine in a Chinese population setting. In addition, given that PCV7 is not currently in widespread use in China, it is particularly relevant that many regional, Asian-specific studies have focused on PCV7, providing a set of relevant references with which our results can be suitably compared.
Methods

Model Structure
To estimate outcomes associated with various vaccination strategies, a previously developed decision-analytic model designed for pneumococcal disease and outcomes of pneumococcal infection [20] was adapted to estimate the health outcomes from including the PCV7 vaccine into the routine vaccination schedule for a birth cohort of infants in Shanghai using a cross-sectional analysis over a 1-year period. The clinical starting point of the model is the vaccination strategy, comparing the case of no vaccinations to a case in which the vaccination coverage level is 85% for all newly born infants in Shanghai. Vaccine administration for the birth cohort occurs with a primary series of three doses in the first 6 months and a booster dose at age 12 months. Individuals within the model had a probability of contracting invasive pneumococcal disease (bacteremia and meningitis), all-cause pneumonia, or allcause otitis media. Outcomes were calculated over a 1-year period that was assumed to occur at a point at which the vaccine effects had reached a steady state, approximately 5 to 7 years after the introduction of the vaccine. Disease cases were estimated on the basis of disease incidence, serotype coverage, and both the direct effect of the vaccine and the indirect effect from herd protection on the unvaccinated population.
Estimates of the Shanghai population by age for 2011 are based on data from the 6th Population Survey of Shanghai [21] .
The population within the model is broken up into seven age groups (o2, 2-4, 5-17, 18-34, 35-49, 50-64, and 65þ y). All children in the model younger than 5 years are considered to have been vaccinated in previous periods. The birth cohort, consisting of all children in the model younger than 12 months, is assumed to receive the infant series and booster dose in the current period with a vaccine coverage rate of 85%. This level of vaccine coverage is consistent with observed levels of coverage in the United States [22] and is therefore considered a more appropriate level of coverage expectation than the standard universal coverage hypothesis often used in similar analyses of vaccine costeffectiveness studies. Based on population estimates for 2011, this incoming birth cohort is considered to be 0.88% of the total population of Shanghai, or approximately 202,568 individuals [21] . All children aged 5 years or older and adults are considered unvaccinated during all stages in the model.
Outcomes are assessed as a cross-sectional analysis over a 1-year period, which was assumed to occur after the vaccine effects have reached a steady state, for the entire population of Shanghai to capture both the direct benefits for the vaccinated population and the indirect benefits of herd protection among the unvaccinated. The disease states incorporated into the model include invasive pneumococcal disease (bacteremia and meningitis), all-cause pneumonia (inpatient and outpatient), and allcause otitis media (mild, and moderate to severe). Disease states within the model are not mutually exclusive, so it is considered possible for individuals to experience multiple pneumococcalrelated outcomes during the annual cycle. The model calculates the number of estimated pneumococcal infections for each age grouping and the anticipated mortality associated with these events.
Cost inputs included in the model and the cost-effectiveness results were calculated from a payer perspective. The cost data within the model include both the direct medical costs of treatment for each disease state and age group and the cost of the vaccine per dose and the direct cost associated with administering the vaccine. The cost-effectiveness outcomes calculated include cost-per-life-year saved, cost-per-quality-adjusted-lifeyear (QALY) gained, and cost-per-illness avoided. All cost data are reported using 2011 Chinese yuan, consistent with the source of the cost data incorporated in the model, and discounted at 5.0% per year. Cost-effectiveness outcomes are also reported in U. S. dollars using exchange rates as of July 2011 [23] to facilitate comparisons with previously published cost-effectiveness studies on the PCV7 vaccine from other countries.
Model Parameters and Input Data
Disease Incidence and Case-Fatality Rates Baseline age-specific disease incidence rates and case-fatality rates for disease states included in the model are reported in Table 1 . Because China does not officially require reporting of IPD cases, it is difficult to obtain accurate epidemiologic data regarding IPD incidence in China. As a result, the baseline incidence data and case mortality rates for IPD and all-cause pneumonia were based on estimates from the Taiwan National Health Insurance Administration for the years 2002 to 2007 [24] . The incidence rates for each age group were calculated as the number of observed morbidity cases per 100,000 population to provide the estimated baseline incidence rate. Case-fatality rates for each age group were calculated as the probability of death conditional on having a pneumococcal-related disease by age group. It is also assumed in the model that long-term sequelae can result from meningitis infection. The model assumes, on the basis of published sources, that approximately 13% of meningitis survivors
will suffer from long-term deafness and 7% of meningitis cases will result in other long-term disabilities [25] [26] [27] .
Vaccine Effectiveness
The model incorporates both the direct effect of disease reduction among vaccinated children and the indirect effect on adults and unvaccinated children as a result of herd protection. Estimates of these effects on IPD (pneumococcal bacteremia and pneumococcal meningitis), all-cause pneumonia (inpatient and outpatient), and otitis media (mild, and moderate to severe) are presented in Table 2 .
The direct effectiveness of the vaccine in terms of percent reduction in disease incidence following vaccination was derived from clinical data measuring the effect of PCV7 on the reduction of IPDs as measured by the immune response of healthy children observed in a clinical trial. The efficacy of the vaccine in Chinese children, as assessed by immunologic response 30 to 50 days following the primary immunization series, was found to be similar to that in children in the United States [28] , so U.S. data from published sources on the direct effectiveness of the vaccine on the percent reduction in disease at the time of vaccination was used for model estimation [27] .
Based on vaccine sales information, the current vaccination rate of PCV7 for children younger than 2 years in China is less than 10%. As a result, the vaccination rate in China is not high enough to achieve a herd immunity effect necessary to estimate the indirect effect of PCV7 vaccination at an 85% level of coverage on the unvaccinated population in China. Data on the percent reduction in pneumococcal disease incidence among the unvaccinated population is therefore derived from research done in the United States following the introduction of the PCV7 vaccine into the routine childhood vaccination schedule in the United States [29] .
Cost Data
Cost data for direct medical cost per case of pneumococcal-related disease by age group and costs related to the vaccination of the incoming birth cohort used in the model are reported in Table 3 . Local inpatient cost data on direct medical costs related to pneumococcal disease were collected from de-identified case records from the Shanghai Board of Health Central Information Data Base. This database lists inpatient disease type and expense information from hospitals in Shanghai. The cost data are for confirmed inpatient cases of pneumococcal meningitis, pneumococcal bacteremia, and all-cause pneumonia reported from January to December 2011. The 
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direct medical expenses include hospitalization fees, physician consultation fees, diagnostic tests, operation fees, nursing fees, and medication expenses. Costs by disease type and age group were calculated as the total direct medical expenses for all individuals within that age group during 2011 divided by the total number of patients within that age group. The costs associated with the vaccination program include the cost per dose of the vaccine and estimated administration costs. The average price for the PCV7 vaccine was assumed to be ¥860 per dose on the basis of published vaccine prices in Shanghai [18] . Each vaccinated infant is assumed to receive four doses over the course of the year so that the total vaccine cost per vaccinated infant was estimated to be ¥3440. In addition to the cost of the vaccine, an administration cost of ¥10 per dose was assumed so that the total direct medical cost of vaccination, vaccine cost and administration, for each infant vaccinated within the model was ¥3480.
Cost-Effectiveness Analysis
The model generates estimates for each vaccination strategy over an annual cycle, yielding estimates for the number of pneumococcal disease cases, number of deaths related to pneumococcal disease, number of life-years saved, and the number of QALYs gained. Lifeyears saved as a result of deaths avoided were calculated as the average life expectancies remaining for each age group estimated from life tables for China derived from World Health Organization estimates [30] . These average life expectancies by age group were 80.8 years for ages 0 to 2 years, 77.0 years for ages 2 to 4 years, 65.5 years for ages 5 to 17 years, 51.1 years for ages 18 to 34 years, 36.8 years for ages 35 to 49 years, 23.3 years for ages 50 to 64 years, and 9.0 years for ages 65 years and above. QALYs gained were calculated on the basis of the number of life-years spent in each health state multiplied by the associated health state utility weight. The utility weights used in the model for neurological impairment and hearing loss resulting from meningitis and the health utility index were obtained from published sources [31, 32] . Incremental costeffectiveness ratios were calculated by taking the ratio between the difference in costs and the difference in outcomes.
Results
Outcomes
The estimated number of pneumococcal-related disease cases, pneumococcal-related deaths, life-years lost, and QALYs lost predicted by the model for both the no-vaccination strategy and the use of PCV7 are reported in Table 4 . Also included in Table 4 are the estimated, differential effects on each of these health outcomes resulting from the inclusion of the PCV7 vaccine into the City Immunity Program in Shanghai. The model predicts that the direct effect of including the PCV7 vaccine into the routine vaccination schedule would result in a reduction in the number of pneumococcal disease cases among the vaccinated population by 29,433 during a given year once vaccine steady state has been achieved. Among these are 7,190 cases of hospitalizations resulting from pneumococcal infection, caused by bacteremia, meningitis, or all-cause pneumonia among children younger than 5 years. When the indirect effects of vaccination due to herd protection among the unvaccinated population are also considered, the total number of pneumococcal-related disease cases prevented increases to 112,629.
Costs
Estimated costs, measured in 2011 Chinese yuan, from pneumococcal-related disease and vaccination strategy are reported in Table 5 . The model estimates that the inclusion of the PCV7 vaccine into the routine vaccination schedule in Shanghai would result in a reduction of approximately ¥28,036,721 in direct medical care expenses among the vaccinated population. When the additional effect on the unvaccinated population is taken into account, this figure rises to a total level of savings of ¥187,923,359 in medical care expenses associated with treatment for pneumococcal-related diseases during the initial year following the implementation of the vaccination policy. The direct vaccination program costs were estimated to be ¥599,198,880 for the incoming birth cohort. Most of this was due to the cost of the actual vaccine. The sum of both the changes in direct medical expenses for the treatment of pneumococcal-related disease and the direct costs of the vaccination program resulted in a total cost increase of ¥411,275,520.
Cost-Effectiveness
The incremental cost-effectiveness ratios for the model are presented in Table 6 . When including only the benefits accruing to the vaccinated cohort, the results show a cost-per-life-year saved ratio of ¥2,230,979 (US $345,086) and a cost-per-QALY gained of ¥2,434,054 (US $376,497). When adding the indirect benefits from the unvaccinated children and adults due to herd protection, however, the costper-life-year saved ratio becomes ¥37,468 (US $5,796) and the costper-QALY gained becomes ¥41,603 (US $6,435). 2 0 1 4 ) 1 9 7 -2 0 4 PCV7, 7-valent pneumococcal conjugate vaccine; QALY, quality-adjusted life-year.
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Sensitivity Analysis
A series of univariate sensitivity analyses were performed to test the sensitivity of the results to several key data input parameters. The ranges of the parameters selected correspond to previously published articles on the cost-effectiveness of PCV7 in other countries in Asia. This analysis was performed on the vaccine cost (Ϯ25% of base case) [16] , vaccine coverage level (Ϯ10% of base case) [13] , vaccine serotype coverage (Ϯ5% of base-case values) [13, 15] , and the percent reduction in disease incidence for the indirect effect in the model (Ϯ5% of the base-case incidence reduction values). The results of the sensitivity analyses are reported in Table 7 . All incremental cost-effectiveness values shown include both the direct effect and the indirect effect of the vaccine. The model results were the least sensitive to changes in the vaccine serotype coverage, with a range of ¥44 (US $7) between the high and low values considered in the analysis for the costper-life-year saved measure. Alterations in vaccine price and vaccine coverage rate showed slightly higher variation, with ranges for the cost-per-life-year-saved measure of ¥29,958 (US $4,634) and ¥12,209 (US $1,889), respectively. In all cases, the results remained highly cost-effective and were consistent with previously published results from other countries in Asia [13, 15, 16] . The cost-effectiveness outcomes were most sensitive to changes in the percent reduction in disease incidence among the unvaccinated population, with a cost-per-life-year saved range of ¥84,041 (US $12,999).
Discussion
Several studies have examined both the clinical and economic benefits of the PCV7 vaccine in various countries around the world, but there has yet to be a study that addresses the costeffectiveness of including PCV7 into the routine vaccination schedule in China using local economic and epidemiological data. This study bridges that gap by applying data on disease outcomes and direct medical costs from local and regional sources to a mathematical model designed to estimate the public health impact and the cost-effectiveness of the pneumococcal vaccine by incorporating both the direct effect on vaccinated children and the indirect effect of herd protection on unvaccinated children and adults in Shanghai.
According to the World Health Organization's pharmacoeconomic evaluation criteria, if the incremental cost-effectiveness ratio is found to be within three times the average per-capita income of that region, then the intervention would be considered costeffective [33] . The 2011 per capita yearly income of Shanghai was estimated to be ¥82,560 (US $12,770) [34] . When the direct effect of introducing the PCV7 vaccine into the routine vaccination schedule in Shanghai alone is considered, the results suggest that the intervention would not be regarded as cost-effective under that guideline. Our study yields values for incremental costeffectiveness ratios (cost-per-life-year saved and cost-per-QALY gained) that are substantially higher than the thresholds established by the World Health Organization as the appropriate cutoff for considering a health intervention to be cost-effective to implement. When the full effect of the vaccine on both the vaccinated population and the unvaccinated population is considered, however, then the resulting cost-effectiveness ratios are 45.4% and 50.4% of the 2011 per-capita income in Shanghai for the cost-perlife-year saved and cost-per-QALY gained measures, respectively, which is within the acceptable threshold to be considered a costeffective intervention.
The indirect effects resulting from herd immunity are the major driver of the cost-effectiveness of the PCV7 vaccine in this study. Indirect effects account for approximately 73.9% of the disease cases prevented, 98.8% of the lives saved, and 97.7% of the life-years gained as a result of the inclusion of the vaccine. The evidence supporting the existence of this effect and its impact has been growing over the decade since the introduction of the PCV7 vaccine into the routine vaccination schedule in the United States [5, 7, 35] .
Our results, suggesting the importance of the indirect effects in determining the cost-effectiveness of the vaccine, are largely in line with other cost-effectiveness studies of PCV7 on populations in Asia incorporating both direct and indirect effects of herd protection on the unvaccinated population. A study for Malaysia found a cost-per-life-year saved ratio of $10,261 when both the direct and indirect effects from herd immunity on the adult population were included in the analysis [13] . A study for Taiwan found a cost-per-life-year gained ratio of $474,034 when only direct effects were included and a ratio of $37,155 when both direct and indirect effects were incorporated into the analysis Table 7 -Sensitivity analysis.
Parameter varied Range of values
Cost-per-life-year saved (US$)
Cost-per-QALY gained (US$) [12] . In Singapore, it was estimated that the cost-per-QALY gained would be $231,971 without considering herd protection and $43,275 when herd protection was incorporated [16] . In Hong Kong, an analysis of the introduction of universal vaccination with PCV7 among infants over a 10-year time horizon that also included both direct and indirect effects resulted in a cost-perlife-year gained ratio of $6460 [15] . In studies in which the results without the inclusion of herd protection were reported, the costeffectiveness ratios suggest that vaccination with PCV7 would not be considered cost-effective. In all cases in which both direct and indirect effects were incorporated into the analysis, however, the results were found to be cost-effective based on World Health Organization guidelines [32] . The study, as implemented, is subject to a number of qualifications due to the lack of data specific to the target population. China does not officially require reporting of IPD cases, so it is difficult to derive incidence and case-fatality rates for pneumococcal-related diseases using local Chinese data. To derive the incidence and mortality data used in the model required the combining of data from various sources. IPD incidence and mortality data were collected from the Taiwan National Health Insurance Administration for the years 2002 to 2007, the PCV7 effectiveness data were derived from publicly available references and some organizational internal archival data, and the demographic data were collected from the 6th Population Survey of Shanghai. The authors note that the process of interpreting and synthesizing data derived from such a variety of sources is subject to potential bias. It also should be noted that population factors such as population density may differ significantly across regions. It is likely that in a city as densely populated as Shanghai that the use of epidemiological data from sources derived from other regions may not accurately reflect the degree of disease transmission present in Shanghai. Given the infectious nature of pneumococcal disease, it is plausible that the indirect effects estimated in this study may differ from the realized indirect effects. As demonstrated in the sensitivity analysis, the model results are particularly sensitive to changes in the indirect effects on disease incidence among the unvaccinated population. If this study is underestimating the effect of herd protection, then the actual cost-effectiveness outcomes may be considerably lower than our base-case estimates would suggest.
Conclusions
Currently, the PCV7 vaccine is not included in the routine vaccination schedule in China. The results of this study suggest that, for Shanghai, the inclusion of the PCV7 vaccine into the routine vaccination schedule for children would result in a substantial reduction in the number of pneumococcal-related diseases and deaths, particularly among the unvaccinated adult population because of the existence of herd protection. At the population level, the vaccine is found to be cost-effective based on the World Health Organization's threshold for costeffectiveness and would, therefore, likely be a worthwhile inclusion into the City Immunity Program in Shanghai.
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